P. Carter

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

F. Bymaster, G. Nomikos, C. Felder, 2002, The Journal of pharmacology and experimental therapeutics.

Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

F. Bymaster, A. Fink-Jensen, C. Mitch, 1998, Brain Research.

Investigations into the physiological role of muscarinic M2 and M4 muscarinic and M4 receptor subtypes using receptor knockout mice.

F. Bymaster, C. Felder, P. Carter, 2001, Life sciences.

Receptor reserve of phosphoinositide-coupled muscarinic receptors in mouse hippocampus in vivo

F. Bymaster, C. Felder, P. Carter, 2001, Brain Research.

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

D. Wong, K. Perry, F. Bymaster, 2002, Psychopharmacology.

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine‐induced seizure activity

J. Wess, F. Bymaster, D. McKinzie, 2003, The European journal of neuroscience.